Crispr news

1 verified briefing on Crispr. Each story includes a plain-English summary, why it matters, and the concrete action engineering teams should take.

Impact

Tech Updates

Gene-editing drug lowers bad cholesterol

An early clinical trial for a new gene-editing therapy shows promising results. A single dose of the drug, VERVE-102, significantly lowered "bad" cholesterol levels in a small group of patients. The therapy aims to provide a long-term solution with a one-time treatment.

Ars Technica·5h ago·1 min read

Read full

Feed Explore Ask Alerts Saved Profile

Tech intelligence for engineering teams

Short, verified briefings on AI, cybersecurity, infrastructure, and data — with the analysis and action steps that matter. Every briefing is sourced, fact-checked, and bylined to a named editor.

[email protected]Story tips & corrections welcomeHow we report →

The Notifire briefing

Verified tech intelligence in your inbox — AI, security, infra, and data.

The day's most important tech briefings. No spam, unsubscribe anytime.

Sections